874 Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGFβ signaling, as novel single-agent immunotherapy
Main Authors: | Chaitali Dey, Srinivas Reddy Boreddy, Reshmi Nair, Arindam Banerjee, Anshu Kuriakose, Prashant Kumar Pandey, Meena Shri, Shruthi Rao, Bhadravathi Marigowda Shivakumar, Moni Abhram Kuriakose, Ram Bhupal Reddy, Amritha Suresh, Praveen Reddy Moole, Usha Bughani, Seng-Lai Tan, Pradip Nair |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
by: Usha Bughani, et al.
Published: (2017-01-01) -
1426 Combination with BCA101 improves the efficacy of KRAS-G12C inhibitor and overcomes G12C inhibitor-induced resistance in lung and colon cancer cell lines
by: Rachel Salazar, et al.
Published: (2023-11-01) -
Molecular prognosticators in clinically and pathologically distinct cohorts of head and neck squamous cell carcinoma-A meta-analysis approach.
by: Ram Bhupal Reddy, et al.
Published: (2019-01-01) -
Strategies to improve oral cancer outcome in high-prevalent, low-resource setting
by: Moni Abraham Kuriakose
Published: (2018-01-01) -
Tensor Facia Lata-iliac crest osteocutaneous flap for orbitomaxillary reconstruction: A preliminary report
by: Iyer Subramania, et al.
Published: (2010-01-01)